Sitagliptin Patent Expiration
Sitagliptin was first introduced by Zydus Lifesciences Global Fze
Sitagliptin Patents
Given below is the list of patents protecting Sitagliptin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zituvio | US10925871 | Pharmaceutical compositions of sitagliptin | Feb 25, 2035 | Zydus Lifesciences |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sitagliptin's patents.
Latest Legal Activities on Sitagliptin's Patents
Given below is the list recent legal activities going on the following patents of Sitagliptin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 23 Feb, 2021 | US10925871 |
| Patent Issue Date Used in PTA Calculation Critical | 23 Feb, 2021 | US10925871 |
| Email Notification Critical | 04 Feb, 2021 | US10925871 |
| Issue Notification Mailed Critical | 03 Feb, 2021 | US10925871 |
| Dispatch to FDC | 25 Jan, 2021 | US10925871 |
| Dispatch to FDC | 22 Jan, 2021 | US10925871 |
| Application Is Considered Ready for Issue Critical | 19 Jan, 2021 | US10925871 |
| Issue Fee Payment Verified Critical | 19 Jan, 2021 | US10925871 |
| Issue Fee Payment Received Critical | 19 Jan, 2021 | US10925871 |
| Issue Fee Payment Verified Critical | 18 Jan, 2021 | US10925871 |
Sitagliptin's Family Patents
